Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression
- PMID: 2044220
- PMCID: PMC1535440
Expression of interleukin-1 alpha, interleukin-1 beta and interleukin-6 in chronic B lymphocytic leukaemia (B-CLL) cells from patients at different stages of disease progression
Abstract
We have previously found that isolated B-CLL cells from progressive disease produce less interleukin-1 beta (IL-1 beta) as compared with cells from patients with indolent disease. Here we extend that finding to include measurements of IL-1 beta mRNA and secretion of IL-1 alpha and interleukin-6 (IL-6). As before, a lower production of IL-1 beta was found in cells from progressive disease. IL-6 was produced by cells from patients at all stages, with a tendency to follow the IL-1 beta production. Low secretion of IL-1 alpha was noted. When viable cells were permeabilized and analysed at the single cell level with monoclonal antibodies, most B-CLL cells were found to contain IL-1 alpha. A minor fraction of non-permeabilized cells expressed IL-1 alpha at the cell membrane. However, only small fractions of cells were positive for intracellular IL-1 beta (less than 1%) and almost no IL-6-positive cells were found. We conclude that either IL-1 beta and IL-6 are produced by a minor population of undefined cells, or that a more sensitive in situ method is needed to detect production of these cytokines in B-CLL cells. The possible biological significance of secreted, and membrane-expressed helper factors in B-CLL is discussed.
Similar articles
-
Production of intracellular IL-2, TNF-alpha, and IFN-gamma by T cells in B-CLL.Cytometry B Clin Cytom. 2003 Nov;56(1):23-9. doi: 10.1002/cyto.b.10052. Cytometry B Clin Cytom. 2003. PMID: 14582134
-
Interleukin-1 beta, interleukin-1 receptor antagonist and interleukin-6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: correlation with prognostic parameters.Haematologica. 2000 Jun;85(6):600-6. Haematologica. 2000. PMID: 10870116
-
Exogenous interleukin 2 (IL 2) reconstitutes deficient in vitro T-cell growth of patients with chronic lymphocytic leukemia of B-cell lineage (B-CLL).Anticancer Res. 1990 Jul-Aug;10(4):929-34. Anticancer Res. 1990. PMID: 2382990
-
Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia.Cancer. 2002 Sep 1;95(5):1071-5. doi: 10.1002/cncr.10772. Cancer. 2002. PMID: 12209693
-
Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy.Br J Haematol. 2004 Dec;127(5):531-42. doi: 10.1111/j.1365-2141.2004.05240.x. Br J Haematol. 2004. PMID: 15566356
Cited by
-
Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop.Ann Hematol. 1994 Jul;69(1):25-31. doi: 10.1007/BF01757344. Ann Hematol. 1994. PMID: 8061104
-
Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.JCI Insight. 2022 Jun 22;7(12):e158243. doi: 10.1172/jci.insight.158243. JCI Insight. 2022. PMID: 35511436 Free PMC article.
-
Humoral mediation for cachexia in tumour-bearing rats.Br J Cancer. 1993 Jan;67(1):15-23. doi: 10.1038/bjc.1993.4. Br J Cancer. 1993. PMID: 8427775 Free PMC article.
-
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?Blood Adv. 2023 Jun 13;7(11):2401-2417. doi: 10.1182/bloodadvances.2022008985. Blood Adv. 2023. PMID: 36574293 Free PMC article. Review.
-
Cytokine expression in B-CLL in relation to disease progression and in vitro activation.Med Oncol. 1999 Dec;16(4):289-95. doi: 10.1007/BF02785875. Med Oncol. 1999. PMID: 10618692
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials